Know Cancer

forgot password

Phase 1 Clinical Trial of NPI-0052 in Patients With Advanced Solid Tumor Malignancies or Refractory Lymphoma

Phase 1
18 Years
Not Enrolling
Cancer, Lymphomas

Thank you

Trial Information

Phase 1 Clinical Trial of NPI-0052 in Patients With Advanced Solid Tumor Malignancies or Refractory Lymphoma

Inclusion Criteria:

- Histologically-confirmed solid tumor malignancy (patients must be refractory to or
demonstrate unacceptable toxicity towards effective therapy known to provide clinical
benefit for their condition) OR refractory lymphoma (patients whose disease has
progressed despite standard therapy including at least one-doxorubicin-containing
regimen and one anti-CD20 monoclonal antibody-containing regimen.

- KPS ≥70%.

- All Adverse Events of any prior chemotherapy, surgery, or radiotherapy, must have
resolved to NCI CTCAE (v. 3.0) Grade ≤ 1 (except for hemoglobin).

- Adequate bone marrow, renal, adrenal, pancreatic and liver function.

- Signed informed consent.

Exclusion Criteria:

- Administration of chemotherapy, biological, immunotherapy or investigational agent
(therapeutic or diagnostic) within 28 days prior to receipt of study medication (6
weeks for nitrosoureas or mitomycin C; 12 weeks for radioimmunotherapy). Major
surgery, other than diagnostic surgery, within 4 weeks before first study drug
administration. Radiotherapy within 4 weeks.

- Patients that require G-CSF and/or platelet support.

- Patients with ongoing coagulopathies.

- Patients with prior bone marrow transplant therapy (autologous or allogeneic).

- Patients receiving intrathecal therapy.

- Known brain metastases.

- Significant cardiac disease.

- Patients with a prior hypersensitivity reaction of CTCAE Grade ≥ 3 to therapy
containing propylene glycol or ethanol.

- Pregnant or breast-feeding women. Female patients must be postmenopausal, surgically
sterile or they must agree to use acceptable methods of birth control. Female
patients with childbearing potential must have a negative serum pregnancy test. Male
patients must be surgically sterile or agree to use an acceptable method of

- Concurrent, active secondary malignancy for which the patient is receiving therapy.

- Active uncontrolled bacterial or fungal infection requiring systemic therapy;
infection requiring parenteral antibiotics.

- Known to be positive for HIV; active hepatitis A, B, or C infection.

Type of Study:


Study Design:

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:


Outcome Time Frame:


Safety Issue:


Principal Investigator

Robert Corringham, M.D.

Investigator Role:

Study Director

Investigator Affiliation:

Triphase Research and Development I Corp, Chief Medical Officer


United States: Food and Drug Administration

Study ID:




Start Date:

May 2006

Completion Date:

March 2010

Related Keywords:

  • Cancer
  • Lymphomas
  • cutaneous lymphoma
  • marginal zone lymphoma
  • Lymphoma



Memorial Sloan-Kettering Cancer CenterNew York, New York  10021
Univ. of Texas MD Anderson Cancer CenterHouston, Texas  77030